New Test to Identify PML Risk With Natalizumab in MSNew Test to Identify PML Risk With Natalizumab in MS

The test, which detects low levels of L-selectin in the blood, is said to have a sensitivity of about 90%, and even higher rates when combined with JC virus antibody status. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news